OBJECTIVE: @entity5279 is usually administered because of its antiosteoclastic effects but seems to have anti-inflammatory properties also. @entity17829 is characterized by both @entity79 and @entity32 , indicating that it may respond favorably to @entity5279 's dual mechanism of action. @entity1 AND METHODS: We report five cases of @entity17829 refractory to standard treatments. All @entity1 were taking nonsteroidal anti-inflammatory drugs, either alone or in combination with analgesics, glucocorticoids, and/or second-line drugs. We used intravenous @entity5279 during exacerbations of the disease. The primary evaluation criterion was the reduction in the visual analog scale (VAS) score for @entity158 , and a response was defined as a greater than 50% reduction. RESULTS: Four of the five @entity1 had a response after 1 week. Two of these four @entity1 still met the response criterion after 3 months. Four of the five @entity1 were able to reduce the dosage of their usual medications. In one @entity1 , @entity5279 therapy was associated with an increase in the intervals between exacerbations. Joint Bone

@entity5279 treatment in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory osteitis'] @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate', 'Pamidronate'] @entity17829 :: ('MESH:D020083', 'Disease') :: ['SAPHO syndrome'] @entity79 :: ('MESH:D001847', 'Disease') :: ['increased bone remodeling'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain']
@entity17829 :: (MESH:D020083,Disease) :: ['SAPHO syndrome']
